Press & news
Fidelis Sustainability Distribution and Biofidelity Collaborate to Bring Rapid Precision Genomic Testing to Veterans Administration (VA) Customers
Jan 24. 2024
Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make ASPYRE®-Lung available to VA Medical Centers and active military institutions across the US.
Biofidelity launches ASPYRE®-Lung reagents, enabling laboratories worldwide to perform rapid precision genomic analysis
Dec 6. 2023
ASPYRE-Lung Research Use Only (RUO) reagents enable localized testing and rapid results across all NCCN guideline recommended genes for non-small cell lung cancer (NSCLC).
Biofidelity announces the commercial launch of ASPYRE®-Lung in the US
Sep 5. 2023
Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.
Simplifying and Speeding Up Genomic Testing and Analysis Using PCR Instruments to Identify Biomarkers with Dr. Barnaby Balmforth Biofidelity
Dec 13. 2023
Dr. Barnaby Balmforth, Co-Founder and CEO of Biofidelity, has a mission to make genomic analysis simpler, faster, and more reliable for treatment decisions. Biofidelity addresses genome sequencing challenges by using a targeted approach and unique technology that allows for local testing using PCR rather than DNA sequencers.
Lung cancer boost as Biofidelity now takes ‘supertest’ to labs worldwide
Dec 7. 2023
Biofidelity, a genomic technology company with UK headquarters at Cambridge Science Park and a US flagship in North Carolina, is enabling laboratories worldwide to perform rapid precision genomic analysis through the launch of its ASPYRE®-Lung reagents.
Biofidelity’s ASPYRE: The future is bright for oncology
Dec 7. 2023
Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simpler, faster analysis of comprehensive genomic biomarkers to existing solutions.